Argus
•
Oct 28, 2026
FTRE: Raising target price to $26.00
Summary
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
RVTY: Raising target price to $170.00
Oct 28, 2026
•
RVTY
PHIN: What does Argus have to say about PHIN?
Oct 28, 2026
•
PHIN
PRVA: Lowering target price to $21.00
Oct 28, 2026
•
PRVA
AZTA: Raising target price to $41.00
Oct 28, 2026
•
AZTA
VSTS: Raising target price to $16.00
Oct 28, 2026
•
VSTS
